FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110256937> ?p ?o ?g. }

• W2110256937 endingPage "60" @default.
• W2110256937 startingPage "49" @default.
• W2110256937 abstract "Recent studies show that ω-3 polyunsaturated fatty acids (PUFAs) have the capacity to modulate cancer outcomes. The body responds to cancer in the same way that it responds to inflammation and wound healing. Nutrients with anti-inflammatory effects could therefore be expected to play a role in cancer treatment. This review focuses on the role of ω-3 PUFAs in tumourigenesis and cancer cachexia. Studies indicate that eicosapentaenoic acid (EPA) supplementation may promote arrest of tumour growth and reduce cell proliferation. Patients need to consume at least 2 g of EPA per day for it to have a therapeutic effect. Positive outcomes related to cachexia include diminished weight loss, increased appetite, improved quality of life and prolonged survival, although there is controversy regarding these clinical outcomes. The effects of ω-3 PUFAs on tumourigenesis and cachexia are viewed in the context of altered lipid and protein metabolism. This altered metabolism usually experienced by cancer patients results in increased formation of proinflammatory eicosanoids and cytokines. Cytokines play an indirect role by stimulating the production of arachidonic acid-derived eicosanoids, which support inflammation, cell proliferation and angiogenesis, and inhibit apoptosis. It can be concluded that ω-3 PUFA supplementation offers a means of augmenting cancer therapy, inhibiting tumourigenesis and possibly contributing to cachexia alleviation.&#x0D; &#x0D; Opsomming&#x0D; Onlangse studies toon dat ω-3-poli-onversadigde vetsure (POVSe) oor die vermoë beskik om kankeruitkomste te moduleer. Die liggaam reageer op kanker op dieselfde wyse as wat dit op inflammasie en wondgenesing reageer. Daar kan dus verwag word dat voedingstowwe met ‘n anti-inflammatoriese uitwerking ‘n rol in die behandeling van kanker kan speel. In hierdie oorsig word daar op die rol van ω-3-POVSe in tumorigenese en kankerkageksie gefokus. Studies dui daarop dat eikosapentanoënsuur- (EPS-)aanvulling tumorgroei moontlik kan stuit en selproliferasie verlaag. Pasiënte moet minstens 2 g EPS per dag inneem om ‘n terapeutiese uitwerking te verseker. Positiewe uitkomste verbonde aan kageksie sluit minder gewigsverlies, beter eetlus, beter lewensgehalte en langer oorlewing in, hoewel daar ‘n geskil bestaan oor hierdie kliniese uitkomste. Die uitwerking van ω-3-POVSe op tumorigenese en kageksie word in die konteks van gewysigde lipied- en proteïenmetabolisme beskou. Die metabolisme wat dikwels in kankerpasiënte voorkom, lei tot ‘n verhoogde vorming van pro-inflammatoriese eikosanoïede en sitokiene. Sitokiene speel ook ‘n indirekte rol deur die produksie van aragidoonsuur-afkomstige eikosanoïede te stimuleer. Laasgenoemde ondersteun inflammasie, selproliferasie en angiogenese, en inhibeer apoptose. Die gevolgtrekking kan gemaak word dat ω-3-POVS-aanvulling ‘n manier is om kankerterapie uit te brei, tumorigenese te inhibeer en moontlik tot die verligting van kageksie by te dra." @default.
• W2110256937 created "2016-06-24" @default.
• W2110256937 creator A5010836110 @default.
• W2110256937 creator A5071584034 @default.
• W2110256937 date "2008-11-18" @default.
• W2110256937 modified "2023-10-01" @default.
• W2110256937 title "The role of long-chain polyunsaturated fatty acids in the treatment of cancer Cachexia and tumour growth in patients with malignant diseases: A review" @default.
• W2110256937 cites W1482658359 @default.
• W2110256937 cites W1569920675 @default.
• W2110256937 cites W1576404822 @default.
• W2110256937 cites W1580314265 @default.
• W2110256937 cites W1907854530 @default.
• W2110256937 cites W1925777112 @default.
• W2110256937 cites W1934742528 @default.
• W2110256937 cites W1961127914 @default.
• W2110256937 cites W1964113171 @default.
• W2110256937 cites W1965037168 @default.
• W2110256937 cites W1970957601 @default.
• W2110256937 cites W1979462071 @default.
• W2110256937 cites W1979666460 @default.
• W2110256937 cites W1982267436 @default.
• W2110256937 cites W1982347136 @default.
• W2110256937 cites W2015982216 @default.
• W2110256937 cites W2022154147 @default.
• W2110256937 cites W2037898183 @default.
• W2110256937 cites W2043629265 @default.
• W2110256937 cites W2051257813 @default.
• W2110256937 cites W2058118671 @default.
• W2110256937 cites W2059019487 @default.
• W2110256937 cites W2063801815 @default.
• W2110256937 cites W2078608486 @default.
• W2110256937 cites W2089641881 @default.
• W2110256937 cites W2096296897 @default.
• W2110256937 cites W2099451923 @default.
• W2110256937 cites W2100649229 @default.
• W2110256937 cites W2101541068 @default.
• W2110256937 cites W2109956558 @default.
• W2110256937 cites W2121512138 @default.
• W2110256937 cites W2121550440 @default.
• W2110256937 cites W2124047443 @default.
• W2110256937 cites W2134970925 @default.
• W2110256937 cites W2135473096 @default.
• W2110256937 cites W2138397971 @default.
• W2110256937 cites W2151191545 @default.
• W2110256937 cites W2154029199 @default.
• W2110256937 cites W2154055686 @default.
• W2110256937 cites W2158288399 @default.
• W2110256937 cites W2163182756 @default.
• W2110256937 cites W2165724916 @default.
• W2110256937 cites W2165875133 @default.
• W2110256937 cites W2266169372 @default.
• W2110256937 cites W3146925300 @default.
• W2110256937 cites W88210178 @default.
• W2110256937 cites W2071472677 @default.
• W2110256937 doi "https://doi.org/10.4102/hsag.v13i2.279" @default.
• W2110256937 hasPublicationYear "2008" @default.
• W2110256937 type Work @default.
• W2110256937 sameAs 2110256937 @default.
• W2110256937 citedByCount "1" @default.
• W2110256937 countsByYear W21102569372018 @default.
• W2110256937 crossrefType "journal-article" @default.
• W2110256937 hasAuthorship W2110256937A5010836110 @default.
• W2110256937 hasAuthorship W2110256937A5071584034 @default.
• W2110256937 hasBestOaLocation W21102569371 @default.
• W2110256937 hasConcept C121608353 @default.
• W2110256937 hasConcept C126322002 @default.
• W2110256937 hasConcept C134018914 @default.
• W2110256937 hasConcept C164027704 @default.
• W2110256937 hasConcept C181199279 @default.
• W2110256937 hasConcept C19038510 @default.
• W2110256937 hasConcept C2776091944 @default.
• W2110256937 hasConcept C2776914184 @default.
• W2110256937 hasConcept C2777704314 @default.
• W2110256937 hasConcept C2778078955 @default.
• W2110256937 hasConcept C502942594 @default.
• W2110256937 hasConcept C543025807 @default.
• W2110256937 hasConcept C55493867 @default.
• W2110256937 hasConcept C71924100 @default.
• W2110256937 hasConcept C75908981 @default.
• W2110256937 hasConcept C86803240 @default.
• W2110256937 hasConceptScore W2110256937C121608353 @default.
• W2110256937 hasConceptScore W2110256937C126322002 @default.
• W2110256937 hasConceptScore W2110256937C134018914 @default.
• W2110256937 hasConceptScore W2110256937C164027704 @default.
• W2110256937 hasConceptScore W2110256937C181199279 @default.
• W2110256937 hasConceptScore W2110256937C19038510 @default.
• W2110256937 hasConceptScore W2110256937C2776091944 @default.
• W2110256937 hasConceptScore W2110256937C2776914184 @default.
• W2110256937 hasConceptScore W2110256937C2777704314 @default.
• W2110256937 hasConceptScore W2110256937C2778078955 @default.
• W2110256937 hasConceptScore W2110256937C502942594 @default.
• W2110256937 hasConceptScore W2110256937C543025807 @default.
• W2110256937 hasConceptScore W2110256937C55493867 @default.
• W2110256937 hasConceptScore W2110256937C71924100 @default.
• W2110256937 hasConceptScore W2110256937C75908981 @default.
• W2110256937 hasConceptScore W2110256937C86803240 @default.
• W2110256937 hasIssue "2" @default.
• W2110256937 hasLocation W21102569371 @default.

• next